Royal Bank of Canada raised its price target for Sarepta Therapeutics (SRPT) to $182, with other analysts also increasing their targets.
Royal Bank of Canada increased its price target for Sarepta Therapeutics (NASDAQ: SRPT) from $142 to $182, indicating a potential upside of 13.24%. Other analysts also provided insights, with Needham & Company LLC raising its target price to $235, Bank of America increasing it to $213, and Robert W. Baird boosting it to $200. These analysts have 'buy' or 'overweight' ratings on the biotech company's stock.
June 23, 2024
4 Articles